|
John Maraganore
John Maraganore is an American scientist, entrepreneur, and life sciences industry leader. Education John was born in Chicago, Illinois, U.S. in 1962 to Greek immigrant parents. In 1984, he completed his B.A. from University of Chicago in Division of Biological Sciences. In 1985, he completed his M.S. from the University of Chicago in Department of Biochemistry and Molecular Biology. In 1986, Maraganore received his Ph.D. from the University of Chicago in Department of Biochemistry and Molecular Biology. Career Maraganore started his career as a post-doctoral research scientist at Upjohn in Kalamazoo, Michigan, from 1985-86. From 1986-87, he was a senior scientist at Zymogenetics in Seattle, Washington. From 1987-1997, he was a senior scientist, group leader of thrombosis and hemostasis research, director of biological research, director of market and business development, and program executive at Biogen in Cambridge, Massachusetts. At Biogen, he invented bivalirudin, a di ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Scientist
A scientist is a person who conducts scientific research to advance knowledge in an area of the natural sciences. In classical antiquity, there was no real ancient analog of a modern scientist. Instead, philosophers engaged in the philosophical study of nature called natural philosophy, a precursor of natural science. Though Thales (circa 624-545 BC) was arguably the first scientist for describing how cosmic events may be seen as natural, not necessarily caused by gods,Frank N. Magill''The Ancient World: Dictionary of World Biography'', Volume 1 Routledge, 2003 it was not until the 19th century that the term ''scientist'' came into regular use after it was coined by the theologian, philosopher, and historian of science William Whewell in 1833. In modern times, many scientists have advanced degrees in an area of science and pursue careers in various sectors of the economy such as academia, industry, government, and nonprofit environments.'''' History The roles ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Takeda Oncology
Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical. Takeda Oncology's research, development and commercialization activities focused in two therapeutic areas: oncology and inflammation to develop a line of new product candidates. It was one of the first companies to systematically search for genes linked to disease, although none of the drugs which it is marketing or has in clinical trial, with one partial exception, have been the results of that research. It is particularly known for bringing bortezomib (marketed as Velcade) through clinical trials to approval for treatment of patients with multiple myeloma by the U.S. FDA, but has a growing clinical development pipeline of other product candidates. On May 14, 2008, Japanese company Takeda Pharmaceutical announced the completion of its acquisition of Millennium for US$25.00 per share in cash—a deal w ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
N-Lorem
The n-Lorem Foundation is a non-profit organization based in Carlsbad, California, established to develop personalized medicines using antisense RNA in order to treat patients of rare diseases. History The organization was founded by Stanley T. Crooke, former CEO of Ionis Pharmaceuticals and head of research at GlaxoSmithKline, in 2020. The n-Lorem Foundation was established in January 2020 with the goal of taking advantage of the technology developed at Ionis to provide experimental treatments to patients suffering from rare genetic disorders. The kind of patients treated at n-Lorem are those with nano-rare diseases, a term used to describe a disease that affects 1-30 people worldwide. Patients with extremely rare genetic disorders have numerous unique challenges to face when seeking treatment. First, traditional pathways for accessing treatment do not work for such rare diseases. In fact, there are no pathways in place for nano-rare disorders. Second, finding a diagnosis and ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Huntington’s Disease
Huntington's disease (HD), also known as Huntington's chorea, is a neurodegenerative disease that is mostly inherited. The earliest symptoms are often subtle problems with mood or mental abilities. A general lack of coordination and an unsteady gait often follow. It is also a basal ganglia disease causing a hyperkinetic movement disorder known as chorea. As the disease advances, uncoordinated, involuntary body movements of chorea become more apparent. Physical abilities gradually worsen until coordinated movement becomes difficult and the person is unable to talk. Mental abilities generally decline into dementia. The specific symptoms vary somewhat between people. Symptoms usually begin between 30 and 50 years of age but can start at any age. The disease may develop earlier in each successive generation. About eight percent of cases start before the age of 20 years, and are known as ''juvenile HD'', which typically present with the slow movement symptoms of Parkinson's ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
CHDI Foundation
The CHDI Foundation, Inc., is a United States-based non-profit biomedical foundation that aims to "rapidly discover and develop drugs that delay or slow the progression of Huntington's disease", a neurodegenerative genetic disorder that affects muscle coordination and leads to cognitive decline. History CHDI's predecessor, the High Q Foundation, was established in 2002 by a group of private donors. It was officially incorporated in New Jersey on October 17, 2003. Originally, the High Q foundation aimed to identify targets for treatments, while CHDI – the 'Cure Huntington's Disease Initiative' – was a sister organization allied to the Hereditary Disease Foundation, that focused on developing drugs to hit those targets. 'CHDI', which is officially no longer an abbreviation for anything, now refers to the foundation as a whole. In 2012 CHDI adopted a new logo, depicting a tree composed of interconnected circles. According to Simon Noble, CHDI's Director of Scientific Communicat ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Nucleate
In thermodynamics, nucleation is the first step in the formation of either a new thermodynamic phase or structure via self-assembly or self-organization within a substance or mixture. Nucleation is typically defined to be the process that determines how long an observer has to wait before the new phase or self-organized structure appears. For example, if a volume of water is cooled (at atmospheric pressure) below 0°C, it will tend to freeze into ice, but volumes of water cooled only a few degrees below 0°C often stay completely free of ice for long periods (supercooling). At these conditions, nucleation of ice is either slow or does not occur at all. However, at lower temperatures nucleation is fast, and ice crystals appear after little or no delay. Nucleation is a common mechanism which generates first-order phase transitions, and it is the start of the process of forming a new thermodynamic phase. In contrast, new phases at continuous phase transitions start to form immed ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Ariadne Labs
Atul Atmaram Gawande (born November 5, 1965) is an American surgeon, writer, and public health researcher. He practices general and endocrine surgery at Brigham and Women's Hospital in Boston, Massachusetts. He is a professor in the Department of Health Policy and Management at the Harvard T.H. Chan School of Public Health and the Samuel O. Thier Professor of Surgery at Harvard Medical School. In public health, he is executive director of Ariadne Labs, a joint center for health systems innovation, and chairman of Lifebox, a nonprofit that works on reducing deaths in surgery globally. On June 20, 2018, Gawande was named the CEO of healthcare venture Haven, owned by Amazon, Berkshire Hathaway, and JP Morgan Chase and stepped down as CEO in May 2020, remaining as executive chairman while the organization sought a new CEO. He has written extensively on medicine and public health for '' The New Yorker'' and ''Slate'', and is the author of the books '' Complications: A Surge ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Henri Termeer
Henri A. Termeer (February 28, 1946 – May 12, 2017) was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, hea ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Biotechnology Innovation Organization
The Biotechnology Innovation Organization (BIO) is the largest advocacy association in the world representing the biotechnology industry. It was founded in 1993 as the Biotechnology Industry Organization, and changed its name to the Biotechnology Innovation Organization on January 4, 2016. Biotechnology Innovation Organization serves more than 1,100 biotechnology firms, research schools, state biotechnology centers and related associations in the United States and in more than 30 other countries. Activities Annual Conference BIO holds its annual international conference each year in the United States. This conference provides networking, business development and partnering activities that are essential to the biotechnology industry, in which developing products take considerable time and resources and regulatory risks are high. In 2021, BIO shifted its in-person meetings to virtual, due to restrictions and difficulties arising from the COVID-19 pandemic. Lobbying In 2018, BIO s ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Takeda Pharmaceuticals
The is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with Shire). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. History Founding and initial acquisitions (1781-2010) Takeda Pharmaceuticals was founded in 1781, and was incorporated on January 29, 1925. One of the firm's ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Beam Therapeutics
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing, whereby single nucleotides in a DNA sequence can be modified without cutting the DNA, theoretically reducing the likelihood of off-target effects compared to previous CRISPR-based methods. History Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang. Prior to its IPO, the company raised nearly $1 billion in venture capital from investors. In a February 2020 IPO, the company raised $180 million. In January 2022, Pfizer and Beam Therapeutics announced a collaboration to develop therapies for rare diseases using CRISPR. See also * CRISPR Therapeutics * Intellia Therapeut ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Agios Pharmaceuticals
Agios Pharmaceuticals Inc. is a public American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. History In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios. In May 2016, the company announced it would launch partnership with Celgene, developing metabolic immuno-oncology therapies and licensing AG-221 as well as AG-881 to Celgene, potentially garnering Agios $120 million in drug licensing payments. In April 2017, the company raised $250 million in a new stock offering in anticipation o ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
.jpg "Click for more on -> Huntington’s Disease")
